The prospect of silencing disease using RNA interference

JAMA

Volumn 293, Issue 11, 2005, Pages 1367-1373

  Shankar, Premlata ^a   Manjunath, N ^a   Lieberman, Judy ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; CANCER; CLINICAL TRIAL; DRUG COST; GENE FUNCTION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMAN; MAMMAL CELL; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TISSUE INJURY; VIRUS INFECTION; ANIMAL; NEOPLASM; PHYSIOLOGY;

ANIMALS; GENE THERAPY; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; RNA INTERFERENCE; VIRUS DISEASES;

EID: 14844303966     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.11.1367     Document Type: Review

References (70)

1. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool and therapeutic. Annu Rev Med. 2005;56:401-423.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
3. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 1990;2:279-289.
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-854.
5. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
6. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
7. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83-86.
8. Hannon GJ, Conklin DS. RNA interference by short hairpin RNAs expressed in vertebrate cells. Methods Mol Biol. 2004;257:255-266.
9. Paddison PJ, Caudy AA, Sachidanandam R, Hannon GJ. Short hairpin activated gene silencing in mammalian cells. Methods Mol Biol. 2004;265:85-100.
10. Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430:161-164.
11. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov. 2004;3:318-329.
12. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature. 2004;431:371-378.
13. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 1999;13: 3191-3197.
14. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science. 1999;286:950-952.
15. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101:25-33.
16. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells. Nature. 2000;404:293-296.
17. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15:185-197.
18. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science. 2004;305:1434-1437.
19. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo, Biochem Biophys Res Commun. 2002;296:1000-1004.
20. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends Genet. 2004;20: 521-524.
21. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther. 2005;12:5-11.
22. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33: 401-406.
23. Brummelkamp T, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002;2:243-247.
24. Fraser A. RNA interference: human genes hit the big screen. Nature. 2004;428:375-378.
25. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosls tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature. 2003;424:797-801.
26. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347-351.
27. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. 2003;8:769-776.
28. Klein C, Bock CT, Wedemeyer H, et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology. 2003;125:9-18.
29. McCaffrey AP, Nakai H, Pandey K, et at. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol. 2003;21:639-644.
30. Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10:816-820.
31. Dorn G, Patel S, Wotherspoon G, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 2004;32:e49.
32. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis. 2003;9:210-216.
33. Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2004;101:14883-14888.
34. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA. 2004;101:8676-8681.
35. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A. 2004;101:8682-8686.
36. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered SiRNA. Nat Med. 2005;11:50-55.
37. Minakuchi Y, Takeshita f, Kosaka N, et al. Atelo-collagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004;32:e109.
38. Sumimoto H, Yamagata S, Shimizu A, et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther. 2005;12:95-100.
39. Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg. 2004;240:667-674.
40. Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene. 2004;23:4681-4689.
41. Song E, Lee SK, Dykxhoorn DM, et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol. 2003;77:7174-7181.
42. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet, 2003;4:346-358.
43. Chiu YL, Rana TM. SiRNA function in RNA: a chemical modification analysis. RNA. 2003;9: 1034-1048.
44. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432: 173-178.
45. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the Interferon system by short-interfering RNAs. Nat Cell Biol. 2003;5:834-839.
46. Minks MA, West DK, Benvin S, Baglioni C. Structural requirements of double-stranded RNA for the activation of 2′,5′-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J Biol Chem. 1979;254:10180-10183.
47. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol. 2004;172: 6545-6549.
48. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet. 2004;5:355-365.
49. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol. 2003;327:761-766.
50. Lieberman J, Song E, Lee SK, Shankar P. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med. 2003; 9:397-403.
51. Gitlin L, Andino R. Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol. 2003;77:7159-7165.
52. Radhakrishnan SK, Layden TJ, Gartel AL. RNA interference as a new strategy against viral hepatitis. Virology. 2004;323:173-181.
53. He ML, Zheng B, Peng Y, et al. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA. 2003;290:2665-2666.
54. Radhakrishnan S, Gordon J, Del Valle L, Cui J, Khalili K. Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. J Virol. 2004;78:7264-7269.
55. Orba Y, Sawa H, Iwata H, Tanaka S, Nagashima K. Inhibition of virus production in JC virus-infected cells by postinfection RNA interference. J Virol. 2004; 78:7270-7273.
56. Silvestri LS, Taraporewala ZF, Patton JT. Rotavirus replication: plus-sense templates for double-stranded RNA synthesis are made in viroplasms. J Virol. 2004;78:7763-7774.
57. Chang J, Provost P, Taylor JM. Resistance of human hepatitis delta virus RNAs to dicer activity. J Virol. 2003;77:11910-11917.
58. Bitko V, Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 2001;1:34.
59. Li WX, Li H, Lu R, et al. Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A. 2004; 101:1350-1355.
60. Lu S, Cullen BR. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol. 2004;78:12868-12876.
61. Stevenson M. Dissecting HIV-1 through RNA interference. Nat Rev Immunol. 2003;3:851-858.
62. Lee NS, Rossi JJ. Control of HIV-1 replication by RNA interference. Virus Res. 2004;102:53-58.
63. Shankar P, Lieberman J. RNAi and HIV: from here to therapy. In: Butera S, ed. HIV Chemotherapy: A Critical Review. Norwich, England: Horizon Scientific Press. In press.
64. Banerjea A, Li MJ, Bauer G, et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther. 2003;8: 62-71.
65. Friedrich I, Shir A, Klein S, Levitzki A. RNA molecules as anti-cancer agents. Semin Cancer Biol. 2004; 14:223-230.
66. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med. 2004;10:1187-1189.
67. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res. 2004;10:3667-3677.
68. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA. 2003;100:7195-7200.
69. Buckingham SD, Esmaeili B, Wood M, Sattelle DB. RNA interference: from model organisms towards therapy for neural and neuromuscular disorders. Hum Mol Genet. 2004;13(Spec No. 2):R275-R288.
70. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol. 2005;23:222-226.